|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study confirms that in humans, upadacitinib has greater selectivity for JAK1 vs JAK3 relative to the rheumatoid arthritis approved dose of tofacitinib, and results from these analyses informed the selection of upadacitinib IR doses evaluated in phase 2.
|
31448433 |
2020 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Baricitinib is a selective oral inhibitor of JAK1/JAK2 for patients with moderately-to-severely active rheumatoid arthritis (RA).
|
30784354 |
2020 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Upadacitinib (Rinvoq™), an orally-administered Janus kinase 1 (JAK-1) inhibitor, is being developed by AbbVie for the treatment of rheumatoid arthritis.
|
31642025 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Baricitinib is an oral, once-daily selective Janus kinase (JAK1/JAK2) inhibitor for adults with moderately to severely active rheumatoid arthritis (RA).
|
30219772 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This narrative review focuses on the clinical efficacy and safety of baricitinib, but also provides an overview of its mechanism of action in relation to JAK1/JAK2 signalling and discusses the possible clinical implications in patients with RA.
|
30767864 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Upadacitinib is a Janus kinase 1 inhibitor under development for the treatment of several inflammatory disorders including rheumatoid arthritis (RA).
|
29688617 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis.
|
30891131 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the frequency of cardiovascular and venous thromboembolic events in clinical studies of baricitinib, an oral, selective JAK1 and JAK2 inhibitor approved in more than 50 countries for the treatment of moderately-to-severely active rheumatoid arthritis (RA).
|
30663869 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Expert commentary</b>: Upadacitinib has displayed a rapid and favorable efficacy profile in RA but despite being a selective JAK1 inhibitor appears to have a similar safety profile to less-selective Jakinibs.Longer term safety data are awaited.
|
30394138 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The relationships between upadacitinib, an oral selective Janus kinase 1 inhibitor, plasma exposures, and its efficacy (assessed by the American College of Rheumatology 20%/50%/70% responses over time) in moderate-to-severe active rheumatoid arthritis (RA) were characterized using data from 574 patients, on background methotrexate and inadequate response to methotrexate or anti-TNF therapy, from two phase II trials conducted with twice-daily dosing of an immediate-release formulation.
|
31194885 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Upadacitinib is a novel selective Janus kinase 1 inhibitor developed for treatment of rheumatoid arthritis and other autoimmune diseases.
|
30633369 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the efficacy, including capacity for inhibition of radiographic progression, and safety of upadacitinib, a JAK1-selective inhibitor, as compared to placebo or adalimumab in patients with rheumatoid arthritis (RA) who have experienced an inadequate response to methotrexate (MTX).
|
31287230 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Baricitinib, an oral-administrated selective inhibitor of the JAK1 and JAK2, is recently approved for rheumatoid arthritis (RA) treatment.
|
30777075 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> Tofacitinib citrate is an oral Janus kinase 1/3 inhibitor approved for rheumatoid arthritis, ulcerative colitis, and active psoriatic arthritis.
|
31581859 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Baricitinib (Olumiant<sup>®</sup>) is an oral, targeted synthetic DMARD that inhibits JAK1 and JAK2, which are implicated in the pathogenesis of rheumatoid arthritis (RA).
|
29687421 |
2018 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Filgotinib (GS-6034, formerly GLPG0634) is an oral, selective Janus kinase 1 (JAK1) inhibitor that showed early response and sustained efficacy in patients with rheumatoid arthritis and with Crohn's disease.
|
30088677 |
2018 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Upadacitinib is a Janus kinase 1 inhibitor currently being evaluated in phase III rheumatoid arthritis trials.
|
28762476 |
2018 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor.
|
29452839 |
2018 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Baricitinib is an orally administered inhibitor of JAK1 and JAK2 that has been shown to be effective in treating rheumatoid arthritis (RA).
|
30058112 |
2018 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Upadacitinib is a selective inhibitor of Janus kinase 1 and was efficacious in phase 2 studies in patients with moderate-to-severe rheumatoid arthritis.
|
29908669 |
2018 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phase 2 studies with upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, have shown safety and efficacy in the treatment of patients with active rheumatoid arthritis.
|
29908670 |
2018 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hence, Jak1 and Jak2 represent novel therapeutic targets for osteoporosis as well as inflammatory bone diseases including rheumatoid arthritis.
|
28708884 |
2017 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
|
27993828 |
2017 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tofacitinib is a pan JAK inhibitor with specificity for JAK3 over JAK1 over JAK2, which is approved in many countries for the treatment of rheumatoid arthritis (RA), including the United States and the European Union, either as monotherapy or in combination with conventional synthetic disease modifying anti-arthritis drugs (csDMARDs).
|
28829236 |
2017 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the efficacy and safety of different doses and regimens of filgotinib, an oral Janus kinase 1 inhibitor, as add-on treatment to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) and inadequate response to MTX.
|
27993829 |
2017 |